Chih-Lun Hsiao

Title: Chih-Lun Hsiao: Innovator in Antibody Therapeutics

Introduction

Chih-Lun Hsiao is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of biotechnology, particularly in the development of innovative antibody therapies. With a total of 2 patents, Hsiao's work focuses on advancing cancer treatment through targeted immunotherapy.

Latest Patents

One of Hsiao's latest patents is for anti-human PD-L1 antibodies and their uses. This patent describes an anti-PD-L1 antibody, or an antigen-binding fragment thereof, which includes specific heavy and light chain variable regions. These antibodies are designed to be chimeric, humanized, composite, or human antibodies, providing a versatile approach to cancer treatment.

Another significant patent is for anti-colony stimulating factor 1 receptor (CSF1R) antibodies and methods of use for treating cancer. This patent outlines antibodies that specifically bind to the human CSF1 receptor protein, which can inhibit immune regulatory effects in the tumor microenvironment. The antibodies also include fusions with the cytokine inhibitory factor, IL10, enhancing CD8+ T-cell cytotoxicity in cancer treatment.

Career Highlights

Chih-Lun Hsiao has worked with notable organizations such as the Development Center for Biotechnology and Elixiron Immunotherapeutics Limited in Hong Kong. His experience in these institutions has allowed him to collaborate on groundbreaking research and development in the field of immunotherapy.

Collaborations

Hsiao has collaborated with esteemed colleagues, including Cheng-Chou Yu and Shih-Rang Yang. These partnerships have contributed to the advancement of his research and the successful development of innovative therapeutic solutions.

Conclusion

Chih-Lun Hsiao is a key figure in the field of antibody therapeutics, with a focus on developing innovative solutions for cancer treatment. His patents reflect a commitment to advancing medical science and improving patient outcomes.